Skip to content
Axcess News – Lifestyle
Author:
Nxera Pharma
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
August 7, 2026
Nxera Pharma Webinar for Financial Results Presentation – 2Q2026
July 15, 2026
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
June 30, 2026
Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery
June 10, 2026
Nxera’s Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea
June 1, 2026
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies New York Healthcare Conference 2026
May 26, 2026
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
May 11, 2026
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
May 8, 2026
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026
May 1, 2026
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
April 20, 2026
1
2
Next Page
→